menu search

COGT / Cogent Biosciences to Host Investor Webcast to Discuss Updated Clinical Data at ASH from the Ongoing Phase 2 APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis

Cogent Biosciences to Host Investor Webcast to Discuss Updated Clinical Data at ASH from the Ongoing Phase 2 APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis
WALTHAM, Mass. and BOULDER, Colo., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the details of its investor webcast being held on Monday, December 12, 2022 at 8:00 a.m. ET (7:00 a.m. CT) to discuss updated clinical data from its on-going Phase 2 APEX trial evaluating bezuclastinib in patients with Advanced Systemic Mastocytosis being presented at the 64th American Society of Hematology (ASH) Annual Meeting. Read More
Posted: Dec 5 2022, 08:00
Author Name: GlobeNewsWire
Views: 101943

COGT News  

3 Lost Formula Stocks to Consider for the 2nd Half of 2023

By GuruFocus
July 7, 2023

3 Lost Formula Stocks to Consider for the 2nd Half of 2023

Having ended 2022 on a low note, U.S. market indexes have overall shown stronger performances so far in 2023. more_horizontal

Cogent Biosciences: Bezuclastinib's Potential In Treating Gastrointestinal Stromal Tumors

By Seeking Alpha
February 28, 2023

Cogent Biosciences: Bezuclastinib's Potential In Treating Gastrointestinal Stromal Tumors

Cogent Biosciences is a biotechnology company focused on developing solutions for complex medical conditions, with a particular focus on Gastrointesti more_horizontal

Cogent Biosciences: Multiple Inflection Points For FY23, Hold For Now

By Seeking Alpha
December 27, 2022

Cogent Biosciences: Multiple Inflection Points For FY23, Hold For Now

Cogent Biosciences, Inc. is building momentum around its bezuclastinib compound. FY22 saw a number of positive advancements of the company's pipeline. more_horizontal

Cogent Biosciences to Host Investor Webcast to Discuss Updated Clinical Data at ASH from the Ongoing Phase 2 APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis

By GlobeNewsWire
December 5, 2022

Cogent Biosciences to Host Investor Webcast to Discuss Updated Clinical Data at ASH from the Ongoing Phase 2 APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis

WALTHAM, Mass. and BOULDER, Colo., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on dev more_horizontal

Cogent Biosciences (COGT) Stock Soars 90% on Positive Clinical Data

By InvestorPlace
June 10, 2022

Cogent Biosciences (COGT) Stock Soars 90% on Positive Clinical Data

Today, investors in Cogent Biosciences and COGT stock have some promising clinical trial results to look at, as this stock soars. The post Cogent Bio more_horizontal


Search within

Pages Search Results: